Document:

<PAGE>

                                                                   EXHIBIT 10.21

                      ASSIGNMENT OF CROSS-LICENSE AGREEMENT

         This Assignment of Cross-License Agreement (this "Agreement") is made
and entered into as of July 31, 2000 by and among 3DLM, Inc., a California
corporation formerly known as CancerVax, Inc., which is in the process of
changing its name to OncoVac, Inc. ("CancerVax-California"), the John Wayne
Cancer Institute, a California non-profit corporation ("JWCI"), and CancerVax
Corporation, a Delaware corporation ("CancerVax-Delaware").

                                    RECITALS

         A.       CancerVax-California and JWCI are parties to a Cross-License
Agreement dated as of July 24, 1998 (the "JWCI Agreement").

         B.       At the time of entering into the JWCI Agreement, the parties
thereto recognized that further arrangements would need to be made with respect
to CancerVax-California, including the issuance of stock to JWCI and the
transfer to CancerVax-California of technology owned by its majority
shareholder, and that assignment of the JWCI Agreement and such technology to
another corporation was likely.

         C.       CancerVax-California desires to assign all of its rights and
obligations under the JWCI Agreement to CancerVax-Delaware, which is an
affiliate of CancerVax-California by virtue of having the same majority
shareholder, and CancerVax-Delaware desires to assume all such rights and
obligations, upon the terms and conditions set forth herein.

         Now therefore, the parties agree as follows:

                                    AGREEMENT

         1.       DEFINITIONS.

         Unless otherwise defined herein, words used herein as defined words
shall have the meanings set forth in Section 1 of the JWCI Agreement.

         2.       ASSIGNMENT.

         CancerVax-California hereby assigns, as of the date hereof, to
CancerVax-Delaware, all of CancerVax-California's right, title, interest and
obligations under the JWCI Agreement and CancerVax-Delaware hereby accepts such
assignment and assumes all of CancerVax-California's right, title, interest and
obligations under the JWCI Agreement. CancerVax-Delaware further agrees to keep,
perform, comply with

<PAGE>

and fulfill all of the terms and obligations of CancerVax-California under the
JWCI Agreement, as clarified by this Agreement. JWCI acknowledges, consents to
and agrees with the foregoing assignment.

         3.       UPFRONT AND PERIODIC PAYMENTS.

         The parties acknowledge that two (2) payments, each in the amount of
one hundred twenty-five thousand dollars ($125,000.00), have been paid to JWCI
pursuant to Section 4.1 of the JWCI Agreement. Six (6) additional annual
payments of one hundred twenty-five thousand dollars ($125,000.00) each will be
due on the next six (6) anniversaries of June 25, 2000 commencing on June 25,
2001.

         4.       MILESTONE PAYMENT.

         The parties acknowledge that CancerVax-Delaware has paid to JWCI five
hundred thousand dollars ($500,000.00) as a result of receiving equity financing
in the minimum amount of five million dollars ($5,000,000.00) and that such
payment satisfies the milestone payment obligation under Section 4.2 of the JWCI
Agreement.

         5.       STOCK.

         With respect to the obligation under Section 4.2 of the JWCI Agreement
to deliver common stock to JWCI, it is agreed that, upon execution of
CancerVax-Delaware's standard form of stock subscription agreement by JWCI,
CancerVax-Delaware will promptly deliver to JWCI one million two hundred fifty
thousand (1,250,000) shares of common stock of CancerVax-Delaware, which shares
constituted five percent (5%) of the outstanding common stock of
CancerVax-Delaware as of the date of the JWCI Agreement. With the delivery of
such shares of common stock, all obligations under Section 4.2 of the JWCI
Agreement will be satisfied.

         6.       ROYALTY INCOME.

         It is acknowledged that, with the payments made or to be made under
Sections 4.1 and 4.2 of the JWCI Agreement, the "Change Date" under Section 4.3
of the JWCI Agreement will be accomplished once CancerVax-Delaware has paid JWCI
an aggregate of three million five hundred thousand dollars ($3,500,000) from
fifty percent (50%) of any Net Royalties it receives.

         7.       DEADLINE FOR EQUITY FINANCING.

                                       -2-

<PAGE>

         Section 12 of the JWCI Agreement grants JWCI the right to terminate the
JWCI Agreement after notice and opportunity to cure if five million dollars
($5,000,000.00) in equity financing has not been raised or the Patent Rights
have not been licensed to a financially capable partner. By letter dated July
12, 2000, JWCI gave six (6) months' notice of intent to terminate the JWCI
Agreement for failure to comply with such provision. By virtue of
CancerVax-Delaware's receiving five million dollars ($5,000,000.00) in equity
financing on July 18, 2000, JWCI hereby agrees that such provision has been
satisfied and JWCI's notice of intent to terminate shall be null and void.

         8.       CONTINUATION OF JWCI AGREEMENT.

         JWCI and CancerVax-Delaware hereby acknowledge that the JWCI Agreement,
as clarified hereunder, remains in full force and effect and there are no known
breaches or rights to terminate thereunder.

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the day and year first above written.

                                          3 DLM, INC., formerly known as
                                          CANCERVAX, INC.

                                          By: [ILLEGIBLE]
                                              ----------------------------------
                                              Its: Chairman

                                          JOHN WAYNE CANCER INSTITUTE

                                          By: [ILLEGIBLE]
                                              ----------------------------------
                                              Its: COO/Exec V.P.

                                          CANCERVAX CORPORATION

                                          By: [ILLEGIBLE]
                                              ----------------------------------
                                              Its: President

                                       -3-

<PAGE>

                  CONSIDERATION FOR ASSIGNMENT OF CROSS-LICENSE
                                    AGREEMENT

         As an inducement to 3DLM, Inc., a California corporation formerly known
as CancerVax, Inc., which is in the process of changing its name to OncoVac,
Inc. ("CancerVax-California"), to assign as to CancerVax Corporation, a Delaware
corporation ("CancerVax-Delaware"), the Cross-License Agreement between
CancerVax-California and the John Wayne Cancer Institute, a California
non-profit corporation ("JWCI"), dated as of July 24, 1998 (the "JWCI
Agreement") pursuant to an Assignment of Cross-License Agreement among
CancerVax-California, JWCI and CancerVax-Delaware (the "Assignment Agreement"),
CancerVax-Delaware hereby agrees, effective with the execution of the Assignment
Agreement, to issue to CancerVax-California preferred stock of
CancerVax-Delaware on the same terms and conditions, at the same time, and
having the same rights, preferences and privileges, as CancerVax-Delaware issues
to investors in its next preferred stock financing round following the execution
of the Assignment Agreement (and excluding the proposed recapitalization of
CancerVax-Delaware), the number of shares of such preferred stock to have an
aggregate value of $500,000 based on the acquisition price then paid by such
other investors; provided, however, that CancerVax-California shall execute
agreements and documents that are in substance the same as those executed by the
other preferred stock investors.

         No provision of this Agreement may be waived or amended without the
prior written consent of the parties hereto. This Agreement constitutes the
entire agreement between the parties hereto with respect to the subject matter
hereof and supersedes all prior agreements of the parties relating to the
subject matter hereof. This Agreement shall be binding upon and inure to the
benefit of the parties hereto and their respective successors and assigns. This
Agreement shall be governed by, and construed in accordance with, the internal
laws of the State of California.

                  Dated as of July 31, 2000

                                          CANCERVAX CORPORATION, a Delaware
                                          corporation

                                          By: [ILLEGIBLE]
                                              ----------------------------------
                                              Its: President

<PAGE>

                                          3DLM, INC.,

                                          A California Corporation
                                          f/k/a CancerVax, Inc., which is in the
                                          process of changing its name to
                                          OncoVac, Inc.

                                          By: [ILLEGIBLE]
                                              ----------------------------------
                                              Its: Chairman

                                       -2-<PAGE>

                                                                   EXHIBIT 10.22

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                             CROSS-LICENSE AGREEMENT

         This Cross-Licence Agreement is made and entered into as of July 24,
1998 by and between CancerVax Inc. ("CancerVax") a California corporation, and
the John Wayne Cancer Institute ("JWCI"), a California nonprofit corporation.

                                    RECITALS

A.       Donald L. Morton, M.D. ("Dr. Morton"), has been working in the field of
         vaccines for cancer since 1960. Between 1960 and 1971, while at the
         National Cancer Institute ("NCT"), he developed and tested the first
         autologous cell cancer vaccines. From 1971 to 1991, while a faculty
         member at the University of California, Los Angeles ("UCLA"), he
         developed and commenced human clinical studies of an allogeneic
         cellular vaccine for cancer. While at UCLA he also discovered and
         developed over one hundred (100) human tumor cell lines for evaluation
         and research.

B.       Three (3) of the cell lines discovered and developed by Dr. Morton at
         UCLA formed the basis for the current melanoma vaccine and are the
         subject of two (2) U.S. patent applications which were filed while Dr.
         Morton was at UCLA. The cell lines were released to Dr. Morton by UCLA
         for the purposes claimed in the patent applications and, in accordance
         with federal law, the patent applications were released by the National
         Institute of Health ("NIH"). The patent applications were filed prior
         to the formation of JWCI and have been prosecuted at the personal
         expense of Dr. Morton.

C.       After moving to JWCI, Dr. Morton disclosed to the Board of Directors
         of JWCI (the "JWCI Board") his proprietary interest in allogeneic
         cellular vaccine technology developed at UCLA and his interest in
         continuing research in the field at JWCI. It was recognized that, even
         though JWCI was being allowed to use the cell lines and melanoma
         vaccine for research purposes, the commercialization of the melanoma
         vaccine technology could be subject to any patents issued on Dr.
         Morton's patent applications, which would also require the use of the
         cell lines.

D.       JWCI and Saint John's Health Center have further developed the
         melanoma vaccine based on the cell lines and treated patients with it.
         As a result of such activities and scientific medical publications,
         JWCI and Saint John's Health Center have become the largest center in
         the United States for treating melanoma cancer and have received
         international recognition. Patients from

<PAGE>

         thirty-two (32) countries and forty-eight (48) states have been treated
         for melanoma cancer at Saint John's Health Center using the melanoma
         vaccine.

E.       Of the cell lines discovered and developed by Dr. Morton at UCLA, an
         additional twenty (20) cell lines were assigned to him by UCLA, which
         have not been fully developed or characterized and which are not the
         subject of any pending patent applications or issued patents filed by
         Dr. Morton or, to CancerVax's knowledge, UCLA.

F.       Dr. Morton will be exclusively licensing, directly or indirectly, all
         of his interest in the melanoma vaccine (including patent application
         and related cell lines) and the twenty (20) other undeveloped cell
         lines to CancerVax, which has the right to sublicense them.

G.       CancerVax's mission is to commercialize immunotherapies for cancer,
         including the melanoma vaccine and other allogeneic cellular vaccines
         for cancer. JWCI's mission, in part, is to continue the research and
         development of useful technologies for the treatment of cancer and,
         through collaboration with Saint John's Health Center, to apply such
         technologies to the treatment of patients and for the benefit of
         mankind.

H.       In order to (i) maintain a mutuality of interest, (ii) create an
         environment that is most likely to result in further improvement and
         development of the melanoma vaccine and (iii) create a spirit of
         cooperation and development for other allogeneic vaccines, JWCI desires
         to receive a nonexclusive license from CancerVax to use the melanoma
         vaccine and the twenty (20) other cell lines for research purposes and
         to receive equity in, and certain milestone and royalty payments from,
         CancerVax, and CancerVax desires to receive from JWCI rights to use
         technology developed by JWCI related to the melanoma vaccine and
         certain amount of the melanoma vaccine produced at the present JWCI
         facility, upon the terms and conditions set forth herein.

I.       Dr. Morton is a principal shareholder and director of CancerVax and
         the President of JWCI. Therefore, this Agreement has been reviewed and
         recommended by an independent special committee of the JWCI Board (with
         the advice of consultants and legal counsel) and approved by the
         independent members of the JWCI Board.

                                       -2-

<PAGE>

                                   AGREEMENT

1.       DEFINITIONS

          As used herein, the following terms shall have the meanings set forth
below:

         1.1      "CancerVax License" shall have meaning set forth in Section 3.

         1.2      "Cell Banks" shall have the meaning set forth in Section 13.

         1.3      "Cell Lines" shall mean the human melanoma cell lines
designated as M-10VACC, M-24VACC and M-101VACC, which are the subject matter, in
part, of the Patent Rights, including their predecessors, progeny,
modifications, derivatives or parts thereof.

         1.4      "Change Date" shall have the meaning set forth in Section 4.3.

         1.5      "Co-sponsor" shall have the meaning set forth in Section 2.

         1.6      "FDA" shall mean the U.S. Food and Drug Administration or any
successor agency.

         1.7      "IND" shall have the meaning set forth in Section 2.

         1.8      "JWCI Affiliate" shall mean a nonprofit corporation in which
JWCI owns and controls more than fifty percent (50%) of the equity entitled to
elect directors.

         1.9      "JWCI License" shall have the meaning set forth in Section 2.

         1.10     "JWCI Technology" shall mean all inventions and discoveries,
whether or not patentable, data, information, copyrights, patents and know-how
that relate to any of the Cell Lines, Know-How or Patent Rights, including, but
not limited to, their manufacture, testing ,administration, use, activity or
characteristics, that JWCI or any JWCI Affiliate or Co-sponsor currently or
hereafter develops, owns or controls. Appendix I attached hereto contains a list
of the current types of JWCI Technology.

         1.11     "Know-How" shall mean all inventions and discoveries, whether
or not patentable, data, information, and know-how that relate to the Cell Lines
and the Melanoma Vaccine, including, but not limited to, their manufacture,
testing, administration, use, activity or characteristics, that CancerVax
currently owns or controls.

                                       -3-

<PAGE>

         1.12     "Melanoma Vaccine" shall mean the vaccine for the treatment of
malignant melanoma comprised of the three Cell lines and covered by the Patent
Rights.

         1.13     "Net Sales" shall mean the gross amount invoiced by CancerVax,
its affiliates and its sublicensees for the Melanoma Vaccine, less

                  (a)      trade discounts, credits, rebates, allowances and
adjustments for rejections, recalls or returns;

                  (b)      retroactive price reductions;

                  (c)      sales, excise, value-added and similar taxes or
duties-imposed on the sale and shown on the invoice or otherwise capable of
documentation;

                  (d)      transportation, insurance and other handling
expenses; and

                  (e)      management fees described in and complying with 42
C.F.R. Section 1001.952(j) (or any successor) that are paid during the relevant
time period to group purchasing organizations and that specifically relate to
the Melanoma Vaccine.

         If amounts are invoiced in other than U.S. dollars, Net Sales shall be
converted to U.S. dollars at the rates of exchange in effect on the last
business day of the calendar quarter in which the invoice was issued (as
reported in The Wall Street Journal, Western Edition), or in accordance with any
other reasonable method mutually agreed upon. The sale or transfer of the
Melanoma Vaccine between CancerVax and its affiliates or sublicensees, whether
for internal use or for resale or other disposition, shall not be included in
Net Sales. (Resale of the Melanoma Vaccine to a third party shall be included in
Net Sales.) Also, sales for preclinical, clinical or regulatory purposes shall
not be included in Net Sales.

         If the Melanoma Vaccine is sold in combination (a "Combination
Product") with any active agent, device or other product ("Other Items"), Net
Sales, for purposes of calculating royalties on a Combination Product shall be
calculated by multiplying the Net Sales of the Combination Product by the
fraction A/(A + B), where A is the gross selling price of the Melanoma Vaccine
sold separately (i.e., without the Other Items) and B is the gross selling price
of the Other Items sold separately. In the event the Melanoma Vaccine and Other
Items are not sold separately. Net Sales shall be calculated by multiplying Net
Sales of the Combination Product by the fraction C/(C + D), where C is the
direct and indirect cost of making the components of the Melanoma Vaccine (not
including the Other Items) and D is the direct and indirect

                                       -4-

<PAGE>

cost of making the Other Items of the Combination Product, such cost being
determined in accordance with generally accepted accounting principles.

         1.14     "Other Cell Line License" shall have the meaning set forth in
Section 14.

         1.15     "Other Cell Lines" shall mean cell lines described in Appendix
2 attached hereto that have been licensed to CancerVax by Dr. Morton, with the
right to sublicense, which cell lines are not currently the subject of any
pending patent applications or issued patents, filed by Dr. Morton or CancerVax.

         1.16     "Patent Rights" shall mean the rights of CancerVax in the U.S.
patent applications set forth in Appendix 3 attached hereto, together with any
divisionals, continuations, continuations-in-part and patents or reissued
patents thereon.

         1.17     "Valid Patent Claims" shall mean a claim of an issued,
unexpired patent that has not been (a) held invalid or unenforceable by a final
decision of a court or governmental agency of competent jurisdiction, which
decision is unappealable or was not appealed within the time allowed therefor,
or (b) admitted in writing to be invalid or unenforceable by the holder(s) by
reissue, disclaimer or otherwise.

2.       LICENSE TO JWCI

         Subject to the terms of this Agreement, CancerVax hereby grants to JWCI
a fully paid-up, royalty-free, nonexclusive license under the Patent Rights and
Know-How to make and use the Melanoma Vaccine for noncommercial (except for cost
reimbursement described below) research and educational purposes related to the
treatment of cancer, including the experimental treatment of candidate patients
under an FDA-approved Investigational New Drug application ("IND") held by JWCI
or held jointly by JWCI and any other nonprofit U.S. research or educational
institution affiliated or cooperating with JWCI for purposes of this IND (a
"Co-sponsor") conducted at JWCI, Saint John's Health Center or the Co-sponsor's
facility or conducted at multiple centers under the supervision of JWCI,
including the clinical studies conducted pursuant to NCI grant #PO 12582, and
any compassionate use treatments approved by the FDA on an individual basis that
are under the direction and control of JWCI, provided that the protocols for any
treatment have been reviewed in advance with CancerVax and JWCI has given
CancerVax an opportunity to comment upon such protocols and given due
consideration to CancerVax's comments in finalizing the protocols (the "JWCI
License"). JWCI shall not use the Patent Rights or Know-How for any other
purpose.

                                       -5-

<PAGE>

         Use of the Patent Rights and Know-How under the JWCI License shall be
in accordance with applicable law and, in the case of experimental treatment,
only under an approved IND or FDA-approved compassionate use treatment and in
accordance with institutional review board(s) approval for each clinical site
and applicable regulations of the FDA and California State Food and Drug Bureau
or equivalent agency. Melanoma Vaccine not approved for sale by the FDA shall be
made available to qualifying patients at no cost and without reimbursement to
JWCI from patients, except where the price to be charged has been approved by
(a) the FDA and (b) CancerVax (or its commercial partner), which approval shall
not be unreasonably withheld. From the date on which CancerVax or its affiliate
or sublicensee notifies JWCI that it has received FDA or State of California
approval to sell the Melanoma Vaccine for a clinical indication, all doses of
the Melanoma Vaccine administered to patients under the JWCI License for the
indication shall be purchased from CancerVax or its affiliate or sublicensee at
market price, regardless of any existing research inventory at JWCI; provided,
however, that JWCI may continue to make and use its existing research inventory
of Melanoma Vaccine for human clinical testing for indications for which FDA
approval has not been received and may purchase from CancerVax at wholesale
prices any Melanoma Vaccine that CancerVax has available for sale after FDA
product approval and that is to be used by JWCI for research and educational
purposes (i.e., non FDA-approved indications) in accordance with this Section 2.

         JWCI shall have the right to sublicense its rights in the JWCI License
to a JWCI Affiliate, such sublicense not to continue after such JWCI Affiliate
ceases being a JWCI Affiliate (including ceases to be a nonprofit corporation).
The JWCI Affiliate shall have no further right to sublicense. JWCI shall
promptly notify CancerVax of any sublicense to a JWCI Affiliate, including its
name, address and scope of sublicense rights. JWCI shall have no right to assign
or otherwise sublicense the JWCI License.

 3.       LICENSE TO CANCERVAX

         Subject to the terms of this Agreement, JWCI hereby grants to CancerVax
an exclusive, worldwide license (with right to sublicense) to use the JWCI
Technology for any purpose, including, but not limited to, the making, having
made, using, offering for sale, selling and importing of the Melanoma Vaccine or
any product based on or incorporating in whole or in part, any of the Cell Lines
(the "CancerVax License"); provided, however, that JWCI retains the nonexclusive
right to use the JWCI Technology for noncommercial educational and research
purposes only as set forth above; provided, further, that CancerVax's license
rights (with right to sublicense) with respect to the items listed in Item 5 of
Appendix I shall be

                                       -6-

<PAGE>
 nonexclusive and that CancerVax's use of patient tissue and other samples may
not materially deplete the supply of such tissue and other samples held in
tissue/sample banks. CancerVax shall not sublicense any patents or patent
applications covering inventions or discoveries hereafter arising and included
in the JWCI Technology to any nonprofit research or educational institution for
use in making an independent application for grant funding from the U.S. federal
government, without the prior consent of JWCI.

         JWCI shall promptly disclose to CancerVax the JWCI Technology.

         CancerVax may, upon request, receive a reasonable amount of
consultation from JWCI and its personnel to understand the JWCI Technology;
however, any special consultation beyond developing a general understanding of
the JWCI Technology shall be provided by JWCI on a reasonable fee basis, subject
to the availability of JWCI personnel. Except as provided in this Agreement,
CancerVax shall not use JWCI's facility or personnel to commercialize the
Melanoma Vaccine, without the prior consent of JWCI, which consent shall be
given by a disinterested officer or member of the JWCI Board.

4.       CONSIDERATION

         In partial consideration of the CancerVax License and other rights
under this Agreement, CancerVax shall pay JWCI the following:

         4.1      UPFRONT AND PERIODIC PAYMENTS

         CancerVax shall pay JWCI One Hundred Twenty-Five Thousand Dollars
($125,000) within ten (10) days after the date that JWCI receives FDA approval
to commence unconditional enrollment of patients in the NCI Phase III trial
pursuant to NCI grant #PO 12582 and One Hundred Twenty-Five Thousand dollars
($125,000) on each of the seven (7) anniversaries of such approval for an
aggregate of One Million Dollars ($1,000,000).

         4.2      MILESTONE PAYMENT AND STOCK

         Within ten (10) days after CancerVax receives an upfront payment in
connection, with licensing its Patent Rights to the Melanoma Vaccine to a
financially capable partner or the closing of an equity financing for CancerVax
in a minimum amount of Five Million Dollars ($5,000,000), CancerVax shall pay
JWCI Five Hundred Thousand Dollars ($500,000) and, upon execution of CancerVax's
standard form of stock subscription agreement by JWCI, deliver to JWCI five
hundred thousand (500,000) shares of Common Stock of CancerVax, which shares
constitute

                                       -7-
<PAGE>

five percent (5%) of the outstanding Common Stock of CancerVax at the time of
this Agreement. Until CancerVax receives such upfront payment or closes such
equity financing, CancerVax shall pay JWCI ten percent (10%) of any such
smaller upfront payments or such smaller equity financings in excess of the
first One Million Dollars ($1,000,000), which amounts shall be creditable
against the Five Hundred Thousand Dollars ($500,000) due under this Section 4.2
and which in the aggregate shall not exceed Five Hundred Thousand Dollars
($500,000).

         4.3      ROYALTY INCOME

         Until CancerVax has paid JWCI an aggregate of Five Million Dollars
($5,000,000) under Sections 4.1 and 4.2 (not including stock) and this Section
4.3 (the "Change Date"), CancerVax shall pay JWCI fifty percent (50%) of any Net
Royalties (as hereafter defined) it receives. For purposes of this Section 4.3,
"Net Royalties" shall mean the amounts received by CancerVax that are a royalty
on sales by its sublicensees of the Melanoma Vaccine covered by the Patent
Rights, reduced by any related royalties CancerVax must pay to any third parties
(other than Dr. Morton) and any out-of-pocket costs (e.g., reasonable attorneys'
fees) incurred by CancerVax in connection with establishing the license
agreements with such sublicensees.

         4.4      ROYALTY AFTER CHANGE DATE

         After the Change Date, CancerVax shall pay JWCI, within sixty (60) days
after the end of each calendar quarter, a royalty in the amount of one percent
(1%) of Net Sales occurring after the Change Date of the Melanoma Vaccine that
is covered by a Valid Patent Claim of the Patent Rights or a patent included in
the JWCI Technology.

5.       MANUFACTURING OF MELANOMA VACCINE

         JWCI grants to CancerVax the option to have the Melanoma Vaccine or
particular Cell Lines manufactured in accordance with current Good Manufacturing
Practices of the FDA ("cGMP") at the JWCI facility for use in humans, including
commercial product for sale, subject to the production capacity of the JWCI
facility, for a period ending on the later of (a) six (6) years after the date
of this Agreement or (b) two (2) years after completion of the clinical trials
to be performed pursuant to NCI grant #PO 12582. The transfer price for such
manufacturing shall be negotiated in good faith by the parties, but the transfer
price shall not exceed cost plus ten percent (10%), with "cost" being
calculated in accordance with generally accepted accounting principles
consistently applied, including product liability insurance, but not including
overhead in excess of thirty-three percent (33%) or amortization of costs

                                      -8-

<PAGE>

for equipment and facility improvements (e.g., fixtures) previously funded or
included charges in previously identified.

         Upon request by CancerVax, JWCI shall allow CancerVax or its designee
to be named in its manufacturing license, shall provide associated data and
information to CancerVax or its designee in conjunction with CancerVax's
exercise of this manufacturing option and shall allow CancerVax or its designee
to inspect and audit the JWCI manufacturing operation and documentation upon
reasonable request.

6.       CONTRIBUTION TO CLINICAL TRIAL FUNDING SHORTFALL

         The parties recognize that JWCI has received NCI grant #PO 12582 to
perform a Phase III clinical study of the Melanoma Vaccine in Stage III melanoma
patients and will apply for other grants to support clinical trials in Stage
II(b) and Stage IV melanoma patients. JWCI shall promptly inform CancerVax if it
appears at any time that there will be shortfall (giving a projected amount and
category for each type of expense shortfall) in funding support for the NCI
and/or other supported trials of JWCI with the Melanoma Vaccine. To the extent
JWCI incurs a shortfall in connection with performing the NCI and/or other
supported trials, CancerVax may, after giving consideration to the status of the
trials and their relationship to CancerVax's commercial mission, elect to fund
all or a portion of such shortfall in order to allow completion of the trials or
& portion thereof.

7.       PATENT PROSECUTION AND MAINTENANCE

         CancerVax shall have no obligation to JWCI to prosecute, maintain or
defend any of the Patent Rights.

         In the event there are any patentable inventions included in the JWCI
Technology, the parties shall discuss and agree upon the process for filing,
prosecuting maintaining and defending patents thereon, including the selection
of the attorneys to handle such matters. In the event CancerVax does not agree
to fund the entire cost of such filing, prosecution, maintenance and defense for
any patents thereon, JWCI will not be obligated to file, prosecute, maintain or
defend, as the case may be, such patents.

8.       DISCLOSURE

         8.1      CONFIDENTIALITY

         Throughout the term of this Agreement and for a period of five (5)
years following termination hereof, each party shall maintain as confidential
and not

                                       -9-

<PAGE>

disclose (except as required to use its license rights hereunder) any
confidential information or proprietary information received from the other
party. The foregoing obligations shall not apply to any information which:

                  (a)      is now in the public domain or becomes generally
                           available to the public through no fault of the
                           receiving party; or

                  (b)      is known to, or in the legal possession of, the
                           receiving party from sources unrelated to the
                           disclosing party as can be demonstrated by
                           documentary evidence; or

                  (c)      is disclosed to the receiving party on a
                           nonconfidential basis by a third party having the
                           right to make such a disclosure.

         8.2     PUBLICATION

         JWCI shall have the right to publish or present information related to
the JWCI Technology and Other Cell Lines, provided such publication or
presentation does not disclose confidential or proprietary information of
CancerVax or its licensees and such publication or representation (and any
revisions thereto) is submitted to CancerVax at least one (1) month prior to
submission of such proposed publication or presentation. Upon notice by
CancerVax and Dr. Morton that a patent application should be filed prior to the
publication or presentation or that CancerVax wishes to comment or suggest
changes to the publication or presentation, submission of the publication or
presentation may be delayed, but no longer than one (1) month after the proposed
submission or presentation date. Authorship of any publications relating to
joint research work by the parties shall be determined by mutual agreement.
Except as set forth in this Section 8.2 and in connection with any government
requirements pursuant to any NIH grants or the FDA, JWCI shall not publish or
disclose to third parties the JWCI Technology or information related to the
Other Cell Lines.

9.       DISCLAIMER

         EXCEPT AS SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY
REPRESENTATIONS OR WARRANTIES TO THE OTHER PARTY WITH RESPECT TO THE PATENT
RIGHTS, KNOW-HOW, CELL LINES, MELANOMA VACCINE OR JWCI TECHNOLOGY OR THEIR USE,
EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY. FITNESS FOR A
PARTICULAR PURPOSE, PATENTABILITY AND NONINFRINGEMENT.

                                      -10-

<PAGE>

10.      INDEMNIFICATION

         JWCI shall indemnify and hold harmless CancerVax and its officers,
directors, employees and agents from and against all claims, demands,
liabilities, damages and expenses (including reasonable attorneys's fees)
arising from or related to the exercise of the JWCI license.

         CancerVax shall indemnify and hold harmless JWCI and its officers,
directors, employees and agents from and against all claims, demands,
liabilities, damages and expenses (including reasonable attorneys' fees) arising
from or related to the exercise of the CancerVax License.

11.     INSURANCE

         JWCI shall maintain adequate liability insurance, consistent with
industry practice, in connection with the exercise of the JWCI License. Upon
request, JWCI shall provide CancerVax with reasonable evidence of such
insurance.

         CancerVax shall maintain adequate liability insurance, consistent with
industry practice, in connection with the exercise of the CancerVax License.
Upon request, CancerVax shall provide JWCI with reasonable evidence of such
insurance.

12.      TERM AND TERMINATION

         Unless terminated earlier, the term of this Agreement shall be for a
term expiring upon the later of (a) the last to expire of any patents included
in the Patent Right and JWCI Technology and (b) ten (10) years from the date
hereof. Upon expiration (but not early termination) of this Agreement, licenses
granted pursuant to Sections 2, 3 and 14 shall become fully paid up,
nonexclusive and perpetual.

         If CancerVax has not raised Five Million Dollars ($5,000,000) in equity
or has not licensed its Patent Rights to a financially capable partner by June
30, 2000, JWCI may terminate this Agreement by giving thereafter six (6)
months' prior written notice of intent to terminate, in which event this
Agreement shall terminate if CancerVax has not raised such amount in equity or
licensed such a partner by the end of such six (6) month period.

         If either party commits a material breach of this Agreement, the other
party shall have the right to terminate the license rights it has granted
hereunder ninety (90) days after giving written notice of the breach unless the
breach has been cured within such ninety (90) day period. The failure or delay
of either party in exercising its rights to licenses granted under this
Agreement shall not constitute a breach of this Agreement or entitle the party
granting the license to recover damages from the other

                                      -11-

<PAGE>

party. Upon termination of this Agreement for any reason, each party shall
promptly return to the other party all forms of confidential information or
material received from the other party that pertains to the license rights,
retaining only one copy of written or electronic confidential information for
archival purposes.

         Upon termination for breach by CancerVax, any sublicensee under the
CancerVax License who is not then in material breach shall have its sublicense
converted to a direct license from JWCI under the terms and conditions of this
Agreement, as further limited and restricted by the terms of the original
sublicense.

         Upon at least thirty (30) days' prior written notice, CancerVax may
terminate the CancerVax License, in which event the parties' rights and
obligations under Sections 4 (except Section 4.1), 5 and 6 shall terminate.

         Any accrued obligations and the provisions of Sections 4.1 (in the
event of any voluntary termination by CancerVax pursuant to the preceding
paragraph), 8, 9, 10 and 12 (second sentence of first paragraph) shall survive
the expiration or termination of this Agreement.

13.      CELL BANKS FOR CELL LINES

         Master cell banks and manufacturer's working cell banks (together, the
"Cell Banks") have been established for each, of the three (3) Cell Lines
on-site and off-site of JWCI's facility. The parties acknowledge that these Cell
Banks have been created, maintained and owned by JWCI. Upon the request of
CancerVax given no later than three (3) years after the date of this Agreement,
JWCI shall deliver to CancerVax or Its designee eighty-five percent (85%) of
each Cell Line in the master Cell Banks and fifty percent(50%) of each Cell line
in the manufacturer's Cell Banks. Until the earlier of three (3) years after the
date of this Agreement or the delivery to CancerVax or its designee of Cell
Lines from the Cell Banks pursuant to the preceding sentence, the Cell Banks
shall be maintained by JWCI in current quantities, reduced by amounts consumed
through reasonable usage which has been documented. In the event either party
needs a sample of Cell Lines, the other party shall reasonably cooperate in
providing such sample with any cost paid by the requesting party.

14.      OTHER CELL LINES

         Subject to the terms of this Agreement, CancerVax hereby grants JWCI a
fully paid-up, royalty-free, nonexclusive license in the United States to use
the Other Cell Lines for noncomercial research and educational purposes,
provided that such use is in accordance with applicable law and, in the case of
experimental treatment, conducted under approved INDs held by JWCI or held
jointly by JWCI and its

                                      -12-
<PAGE>

Co-sponsor at JWCI, Saint John's Health Center or the Co-sponsor's facility or
at other centers under the supervision of JWCI and in accordance with
institutional review board(s) approval for each clinical site and applicable
regulations of the FDA and California State Food and Drug Bureau or equivalent
agency, provided, further, that the protocols for any treatment have been
reviewed in advance with CancerVax and JWCI has given CancerVax an opportunity
to comment upon such protocols and given due consideration to CancerVax's
comments in finalizing the protocols (the "Other Cell Line License"). JWCI shall
not use the Other Cell Lines for any other purpose.

         JWCI shall have the right to sublicense its rights in the Other Cell
Line License to a JWCI Affiliate, such sublicense not to continue after such
JWCI Affiliate ceases being a JWCI Affiliate (including ceases to be a nonprofit
corporation). The JWCI Affiliate shall have no further right to sublicense. JWCI
shall promptly notify CancerVax of any sublicense to a JWCI Affiliate, including
its name, address and scope of sublicense rights. JWCI shall have no right to
assign or otherwise sublicense the Other Cell Line License.

         Use of the Other Cell Lines and Other Cell Line License shall be
subject to the same terms and conditions as set forth in the second paragraph of
Section 2 with respect to the Melanoma Vaccine and JWCI License.

         JWCI shall promptly disclose to CancerVax any inventions, discoveries,
know-how and materials related to the Other Cell Lines made by JWCI, including
information and records from any clinical use, JWCI hereby grants to CancerVax a
nonexclusive, worldwide license (with right to sublicense) to use such items
(except patents issuing thereon) for any purpose, including, but not limited to,
the making having made, using, offering for sale, selling and importing of any
product based on or incorporating, in whole or in part, such items (except
patents issuing thereon) and hereby grants CancerVax an exclusive option to take
an exclusive, worldwide license (with fight to sublicense) to any patents
issuing thereon. Such exclusive license shall be negotiated in good faith by the
parties and shall not require any payments by CancerVax to JWCI greater than a
two percent (2%) royalty on Net Sales of any products covered by any Valid
Patent Claims in such patents and the reimbursement of all of JWCI's patenting
expenses. It is recognized that the right to use the Other Cell Lines for
commercial purposes has not been licensed to JWCI and that any commercial use of
the Other Cell Lines by CancerVax will require a payment of a royalty to UCLA
under certain conditions.

         The cell banks of Other Cell Lines are currently stored at JWCI. Within
three (3) years after the date of this Agreement, CancerVax shall move such cell
banks out of JWCI.

                                      -13-

<PAGE>

15.      REPRESENTATIONS AND WARRANTIES

         15.1     BOTH PARTIES

         Each party hereby represents and warrants to the other party that as of
the date hereof:

                  (a)      It is a corporation duly organized, validly existing
and in good standing under the laws of the state in which it is incorporated.

                  (b)      It (i) has the corporate power and authority and the
legal right to enter into this Agreement and to perform its obligations
hereunder and (ii) has taken all necessary corporate action on its part to
authorize the execution and delivery of this Agreement and the performance of
its obligations hereunder. This Agreement has been duly executed and delivered
on its behalf and constitutes a legal, valid and binding obligation, enforceable
against it in accordance with its terms.

                  (c)      All necessary consents, approvals and authorizations
of all governmental authorities and other persons required to be obtained in
connection with its execution, delivery and performance of this Agreement have
been obtained.

                  (d)      Notwithstanding anything to the contrary in this
Agreement, its execution, delivery and performance of this Agreement (i) will
not conflict with or violate any requirement of applicable laws or regulations
and (ii) will not conflict with, violate or breach or constitute a default or
require any consent under any of its contractual obligations.

         15.2     CANCERVAX

         CancerVax hereby represents and warrants to JWCI that it will have full
license rights to the Patent Rights, Cell Lines (for use with the Patent Rights)
and Other Cell lines and that it owns or controls the Know-How.

          15.3    JWCI

         JWCI represents and warrants to CancerVax that it owns or controls the
JWCI Technology and, to the best of its knowledge, no other party has or will
have an interest in the JWCI Technology or technology developed at JWCI related
to any of the Other Cell Lines.

                                      -14-

<PAGE>
16.      GOVERNMENT RIGHTS

         CancerVax acknowledges that any patentable inventions, cell lines and
other biological material included in the JWCI Technology or technology that may
be licensed pursuant to Section 14 may be subject to the rights and limitations
of 35 U.S.C. Section 200 et seq. and applicable governmental regulations.

17.      MISCELLANEOUS

         17.1     TRANSFER OF CELL LINES AND OTHER CELL LINES

         JWCI shall not transfer the Cell Lines or Other Cell Lines to any other
person or entity without the prior written, approval of CancerVax and without
such person or entity entering into an agreement with CancerVax.

          17.2    ASSIGNMENT OF RIGHTS

         CancerVax shall have the right to sublicense the CancerVax License and
may assign or otherwise transfer its rights or obligations under the CancerVax
License or this Agreement in connection with a merger, consolidation or
reorganization of CancerVax or to an affiliate or purchaser of all or
substantially all of its assets that relate to the subject matter of this
Agreement JWCI does not have the right to assign or otherwise transfer its
rights or obligations under the JWCI License, the Other Cell Line License or
this Agreement, except JWCI may sublicense its rights to a JWCI Affiliate under
the JWCI License and Other Cell Line License as provided in Sections 2 and 14.

          17.3    USE OF NAMES, COPYRIGHTS AND TRADEMARKS

         No party is permitted to use any name, trade name, copyright, trademark
or other designation of the other party in advertising, publicity or other
promotional activity without the prior written consent of the other party unless
required by law.

          17.4    FORCE MAJEURE

         Neither party shall be held liable or responsible to the other party
nor be deemed to have breached this Agreement for failure or delay in fulfilling
or performing any term of this Agreement when such failure or delay is caused by
or results from causes beyond the reasonable control of the affected party,
including, but not limited to, fire, floods, embargoes, war, acts of war
(whether war be declared or not), insurrections, riots, civil commotions,
strikes, lockouts or other labor disturbances, acts of God or acts, omissions or
delays in acting by any governmental authority.

                                      -15-

<PAGE>

         17.5     SEVERABILITY

         Each party intends not to violate any public policy, statutory or
common law, rule, regulation, treaty or decision of any government agency or
executive body thereof of any country or community or association of countries.
If any term or provision of this Agreement is held to be invalid, illegal or
unenforceable by a court or other governmental authority of competent
jurisdiction, such invalidity, illegality or unenforceability shall not affect
any other term or provision of this Agreement, which shall remain in full force
and effect. The holding of a term or provision to be invalid, illegal or
unenforceable in a jurisdiction shall not have any effect on the application of
the term or provision in any other jurisdiction.

          17.6    REVIEW OF AGREEMENT

         This Agreement has been submitted to the scrutiny of both parties and
their counsel and shall be given a fair and reasonable interpretation in
accordance with the words hereof, without consideration or weight being given to
its being drafted, in whole or in part, by or for one of the parties.

          17.7    NOTICES

         Any consent or notice required or permitted to be given or made under
this Agreement by one of the parties hereto to the other shall be in writing,
delivered personally or by facsimile (and promptly confirmed by personal
delivery, first-class U.S. mail or courier), first-class U.S. mail or courier,
postage prepaid (where applicable), addressed to such other party at its address
indicated below, or to such other address as the addressee shall have last
furnished in writing to the addressor and (except as otherwise provided in this
Agreement) shall be effective upon receipt by the addressee.

         If to CancerVax                  CancerVax, Inc.
                                          JAMES LISBAKKEN
                                          PERKINS COIE
                                          1201 THIRD AVE, SEATTLE, WA 98101-3099
                                          Attention: COUNSEL
                                          Fax: 206 583 8500

                                      -16-

<PAGE>

         If to JWCI:                     John Wayne Cancer Institute
                                         2200 Santa Monica Blvd.
                                         Santa Monica, CA
                                                            90404
                                         ATTENTION: James W. Hardin, Executive
                                          Vice President
                                         Fax: (310) 582-7028

         17.8     APPLICABLE LAW

         This Agreement shall be governed by and construed in accordance with
the laws of the State of California, except as set forth, in the immediately
following sentence, and shall not be governed by the United Nations Convention
on Contracts for the International Sale of Goods. The status of information
claimed as a trade secret shall be governed by the law of the jurisdiction in
which the party claiming the information as a trade secret has its principal
place of business.

         17.9     ENTIRE AGREEMENT

         This Agreement contains the entire understanding of the parties with
respect to-Cell Lines, Other Cell Lines, Melanoma Vaccine, Patent Rights,
Know-How and JWCI Technology and supersedes and cancels all prior
understandings, agreements, obligations and claims with respect thereto. The
parties hereby waive and release any claims they may have against each other
(including their officers, directors, employees and agents) with respect to
past use or storage of the Cell Lines, Other Cell Lines and Melanoma Vaccine.
All express or implied agreements and understandings, either oral of written,
heretofore made are expressly merged in and made a part of this Agreement. This
Agreement may be amended, or any term hereof modified, only by a written
instrument duly executed by both parties hereto.

         17.10    HEADINGS

         The captions to the Sections hereof are not a part of this Agreement,
but are merely guides or labels to assist in locating and reading the Sections
hereof.

         17.11    INDEPENDENT CONTRACTORS

         It is expressly understood and agreed that CancerVax and JWCI are and
shall be independent contractors and that the relationship between the two
parties shall not constitute a partnership, joint venture or agency. Neither
CancerVax nor JWCI shall have the authority to make any statements,
representations or commitments of any

                                      -17-

<PAGE>

kind, or to take any action, which shall be binding on the other, without the
prior written consent of the party to do so.

         17.12    U.S. EXPORT LAWS AND REGULATIONS

         Each party represents and warrants to the other that it does not intend
to, nor will it, export from the United States or reexport from any foreign
country, or permit third party to export or reexport, technology or technical
information of the other party to a country where such export or reexport would
be in violation of U.S. Export Administration Regulations.

         17.13    WAIVER

         The waiver by either party hereto of any right hereunder or of a
failure to perform or breach by the other party shall not be deemed a waiver of
any other right hereunder or of any other failure or breach whether of similar
nature or otherwise.

         17.14    COUNTERPARTS

         This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the day and year first above written.

                                          CancerVax, Iac.

                                          By: [ILLEGIBLE]
                                              ----------------------------------

                                          Its: President

                                          John Wayne Cancer Institute

                                          By: /s/ James W. Hardin
                                              ----------------------------------
                                              James W. Hardin, Ph.D.

                                          Its: Executive Vice President
                                              ---------------------------------
                                               Chief Operating Officer

                                      -18-

<PAGE>

                                   APPENDIX 1
                                 JWCI TECHNOLOGY

JWCI Technology includes. but is not limited to:

1.       Methods, procedures and documentation. for the manufacture of the Cell
         Lines and Melanoma Vaccine under cGMP.

2.       Master cell banks and manufacture's working cell banks of all Cell
         Lines.

3.       All data, documentation and other know-how developed by JWCI in any
         clinical trial using the Melanoma Vaccine or any Cell Line, including
         the trials conducted under NCI grant #PO 12582.

4.       Patent and patent applications, including divisionals, continuations,
         continuations-in-part, reissues, extensions and their foreign
         counterparts, of JWCI which pertain to or are improvements to the
         composition or use of the Melanoma Vaccine or to any of the Cell Lines,
         Patent Rights or Know-How, including U.S. patent application no.
         08/427,034 and PCT/US 96/05731.

5.       Patient records, tissue and other samples at JWCI, Saint John's Health
         center and those institutions participating in any clinical study of
         the Melanoma Vaccine, including NCI grant #PO 12582.

                                      -19-

<PAGE>

                                   APPENDIX 2
                                OTHER CELL LINES

<TABLE>
<CAPTION>
--------------------------------------------------------------------
    TISSUE ORIGIN                              CELL LINE DESIGNATION*
--------------------------------------------------------------------
<S>                                            <C>
1.      Melanoma                                      [***]
--------------------------------------------------------------------
2.      Melanoma                                      [***]
--------------------------------------------------------------------
3.      Melanoma                                      [***]
--------------------------------------------------------------------
4.      Melanoma                                      [***]
--------------------------------------------------------------------
5.      Melanoma                                      [***]
--------------------------------------------------------------------
6.      Melanoma                                      [***]
--------------------------------------------------------------------
7.      Melanoma                                      [***]
--------------------------------------------------------------------
8.      Melanoma                                      [***]
--------------------------------------------------------------------
9.      Melanoma                                      [***]
--------------------------------------------------------------------
10.     Melanoma                                      [***]
--------------------------------------------------------------------
11.     Lung Cancer                                   [***]
--------------------------------------------------------------------
12.     Lung Cancer                                   [***]
--------------------------------------------------------------------
13.     Lung Cancer                                   [***]
--------------------------------------------------------------------
14.     Lung Cancer                                   [***]
--------------------------------------------------------------------
15      Colon Cancer                                  [***]
--------------------------------------------------------------------
16.     Sarcoma                                       [***]
--------------------------------------------------------------------
17.     Sarcoma                                       [***]
--------------------------------------------------------------------
18.     Breast Cancer                                 [***]
--------------------------------------------------------------------
19.     Renal Cancer                                  [***]
--------------------------------------------------------------------
20.     Sweat Gland                                   [***]
--------------------------------------------------------------------
</TABLE>

* All designations are preceded by [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                      -20-

<PAGE>

                                   APPENDIX 3
                                  PATENT RIGHTS

1.       Polyvalent Melanoma Vaccine, U.S. patent application No. 07/961,786

2.       Urinary Tumor Associated Antigen-Composition and Methods, U.S. patent
         application No. 08/462,570

3.       A 35kD Tumor Associated Protein Antigen; Uses and Methods of Detection,
         U.S. patent application No. 08/483,128

                                      -21-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}]]